AstraZeneca has launched FluMist Home, the first FDA-approved influenza vaccine available for self- or caregiver administration in the comfort of their own home. This innovative service provides a convenient and accessible option for seasonal flu vaccination, allowing individuals to protect themselves against the flu without having to visit a doctor’s office.
The vaccine is approved for use by adults aged 18-49 years and caregivers for children aged 2-17 years. AstraZeneca has partnered with ASPN Pharmacies, an independent online specialty pharmacy, to provide the vaccine and ensure safe delivery. The service includes clear administration instructions, storage guidance, and disposal information.
According to the Centers for Disease Control and Prevention (CDC), the 2024-2025 influenza season was classified as a high-severity across all age groups in the US, resulting in at least 610,000 hospitalizations and 27,000 deaths. This highlights the importance of increasing influenza vaccination coverage and providing more accessible options to improve immunization rates.
“The launch of FluMist Home is a transformational moment in the evolution of influenza protection,” said Joris Silon, US Country President and Senior Vice President of AstraZeneca. “This innovative service puts consumers in control, offering a seamless experience from determining eligibility to convenient home delivery and administration.”
FLUMIST Home will be available in 34 states covering about 80% of the eligible population for the 2025-26 flu season. The vaccine is also available at doctors’ offices and pharmacies for administration by healthcare professionals across the nation.
It’s essential to note that FLUMIST should not be administered to individuals with severe allergies or certain medical conditions. Consumers should consult their healthcare provider before receiving the vaccine, especially if they have a history of wheezing, asthma, or Guillain-Barré syndrome.
By providing this innovative service, AstraZeneca aims to make flu vaccination more accessible and convenient for individuals and families, ultimately improving protection against influenza and strengthening collective immunity.
Source: https://www.astrazeneca-us.com/media/press-releases/2025/FLUMIST-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery.html